Cited 5 times in
Bioresorbable Vascular Scaffolds Versus Drug-Eluting Stents for Diffuse Long Coronary Narrowings
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 안철민 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 홍성진 | - |
dc.date.accessioned | 2020-06-17T01:01:31Z | - |
dc.date.available | 2020-06-17T01:01:31Z | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 0002-9149 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/176218 | - |
dc.description.abstract | Clinical benefits of bioresorbable vascular scaffold (BVS) implantation for long coronary lesions were not sufficiently evaluated. The efficacy and safety of BVS and metallic everolimus-eluting stent (EES) were compared for the treatment of long coronary narrowings. A total of 341 patients with diffuse long lesions (requiring device length ≥28 mm) were randomized to receive either BVS (n = 171) or EES (n = 170) implantation. The primary endpoint was major adverse cardiovascular events which included death from cardiac cause, myocardial infarction, device thrombosis, or ischemia-driven target-lesion revascularization at 12 months. The trial was terminated early because the manufacturer stopped supplying BVS. The mean lesion length was 32.2 ± 13.1 mm in the BVS group and 35.3 ± 13.0 mm in the EES group. The 12-month follow-up was completed in 332 patients (97.4%). At 12 months, the primary endpoint events occurred in 2 patients (1.2%) in the BVS group and in 4 patients (2.4%) in the EES group (hazard ratio = 0.49, 95% confidence interval = 0.09 to 2.67, p = 0.398). Definite or probable device thrombosis occurred in 1 patient (0.6%) in the BVS group and 1 patient (0.6%) in the EES group (hazard ratio = 1.00, 95% confidence interval = 0.06 to 15.94, p = 0.998). In conclusion, in patients with long native coronary artery disease, significant differences between BVS and EES were not observed regarding the primary composite endpoint of death from cardiac cause, myocardial infarction, device thrombosis, or target-lesion revascularization at 12 months. However, due to the early termination of this trial and a low number of events, the results cannot be considered clinically relevant (clinicalTrials.gov Identifier: NCT02796157). | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Excerpta Medica | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Bioresorbable Vascular Scaffolds Versus Drug-Eluting Stents for Diffuse Long Coronary Narrowings | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jongkwon Seo | - |
dc.contributor.googleauthor | Jung-Min Ahn | - |
dc.contributor.googleauthor | Sung-Jin Hong | - |
dc.contributor.googleauthor | Do-Yoon Kang | - |
dc.contributor.googleauthor | Soon Jun Hong | - |
dc.contributor.googleauthor | Ae-Young Her | - |
dc.contributor.googleauthor | Yong Hoon Kim | - |
dc.contributor.googleauthor | Chul-Min Ahn | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.contributor.googleauthor | Seung-Jung Park | - |
dc.contributor.googleauthor | Duk-Woo Park | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.identifier.doi | 10.1016/j.amjcard.2020.02.031 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A02269 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A04403 | - |
dc.relation.journalcode | J00071 | - |
dc.identifier.eissn | 1879-1913 | - |
dc.identifier.pmid | 32279841 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0002914920302046 | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | 고영국 | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.contributor.affiliatedAuthor | 안철민 | - |
dc.contributor.affiliatedAuthor | 장양수 | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.contributor.affiliatedAuthor | 홍성진 | - |
dc.citation.volume | 125 | - |
dc.citation.number | 111 | - |
dc.citation.startPage | 1624 | - |
dc.citation.endPage | 1630 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CARDIOLOGY, Vol.125(111) : 1624-1630, 2020-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.